EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

2026 Global Initiative for Asthma (GINA) strategy report: executive summary and key changes

Helen K Reddel iD, Keith Allan, Leonard B Bacharier, Matteo Bonini, Arnaud Bourdin iD, Christopher Brightling, Roland Buhl, Jeremiah Chakaya, Alvaro A Cruz, Francine M Ducharme iD, Liesbeth Duijts iD, Louise Fleming und 11 weitere

European Respiratory Journal · 05.11.2026 · 2602304

DOI: 10.1183/13993003.02304-2026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 05.11.2026. Verfasst von Helen K Reddel und 22 weiteren Autor:innen. Beteiligte Einrichtung: Woolcock Institute of Medical Research and Macquarie Medical School, Macquarie University; University of Sydney, Sydney, Australia helen.reddel@woolc…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Global Initiative for Asthma (GINA) Strategy Report provides a comprehensive, annually updated evidence-based approach to asthma diagnosis, assessment, treatment, and prevention across the lifespan. Its central approach is personalized, iterative care based on the Assess-Adjust-Review cycle for both symptom control and reduction of future risk (including severe exacerbations, persistent airflow limitation, and treatment-related harm). GINA emphasizes objective confirmation of diagnosis wherever possible, and regular assessment of lung function, inhaler technique, adherence, multimorbidity, risk factors (including Type-2 biomarkers), and patient goals and preferences. GINA strongly recommends that all adults, adolescents, children and most preschoolers with asthma should receive inhaled corticosteroid (ICS)-containing treatment. GINA recommends against short-acting beta 2 -agonist (SABA)-only treatment. For adults/adolescents, GINA Track 1 using low-dose ICS-formoterol, an anti-inflammatory reliever (AIR), either as-needed-only (AIR-only) or as maintenance-and-reliever therapy (MART), is preferred because of its substantial reduction in severe exacerbations compared with SABA-based regimens, and its simplicity. Age-specific treatment pathways in children also emphasize ICS-containing therapy and exacerbation prevention. For difficult-to-treat and severe asthma, GINA provides structured guidance, emphasizing diagnostic verification, optimization of modifiable factors, inflammatory phenotyping, biologic therapy selection, and (as for all patients) systemic corticosteroid stewardship. Acute exacerbation care incorporates long-term preventive treatment, including post-discharge reassessment of management and action plan. Key 2026 updates include expanded AIR options for adults and children, revised guidance on severe asthma and selection of biologic treatment, and substantial updates to acute asthma management. GINA integrates evidence-based management with shared decision-making, self-management education, implementation, and global advocacy to reduce preventable asthma morbidity and mortality.

Autor:innen und Institutionen

  • Woolcock Institute of Medical Research and Macquarie Medical School, Macquarie University; University of Sydney, Sydney, Australia helen.reddel@woolcock.org.au.
  • Patient Partner, University Hospitals of Leicester, Leicester, UK.
  • Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy and National Heart and Lung Institute (NHLI), Imperial College London, UK.
  • University of Montpellier, Montpellier, France.
  • Institute for Lung Health, Leicester NIHR BRC, University of Leicester, UK.

ORCID-Profile: Helen K Reddel, Arnaud Bourdin, Francine M Ducharme, Liesbeth Duijts, Fanny Wai San Ko, Mark L Levy, Min Zhang, Guy Brusselle

Zitieren

APA

Reddel, H. K., Allan, K., Bacharier, L. B., Bonini, M., Bourdin, A., Brightling, C., Buhl, R., Chakaya, J., Cruz, A. A., Ducharme, F. M., Duijts, L., Fleming, L., Inoue, H., Kaplan, A., Ko, F. W. S., Krishnan, J. A., Levy, M. L., Masekela, R., Pitrez, P. M., …, & Brusselle, G. (2026). 2026 Global Initiative for Asthma (GINA) strategy report: executive summary and key changes. European Respiratory Journal, 2602304. https://doi.org/10.1183/13993003.02304-2026

Vancouver

Reddel HK, Allan K, Bacharier LB, Bonini M, Bourdin A, Brightling C, et al. 2026 Global Initiative for Asthma (GINA) strategy report: executive summary and key changes. European Respiratory Journal. 2026:2602304. doi:10.1183/13993003.02304-2026

BibTeX
@article{Reddel2026,
  author = {Reddel, Helen K and Allan, Keith and Bacharier, Leonard B and Bonini, Matteo and Bourdin, Arnaud and Brightling, Christopher and Buhl, Roland and Chakaya, Jeremiah and Cruz, Alvaro A and Ducharme, Francine M and Duijts, Liesbeth and Fleming, Louise and Inoue, Hiromasa and Kaplan, Alan and Ko, Fanny Wai San and Krishnan, Jerry A and Levy, Mark L and Masekela, Refiloe and Pitrez, Paulo Marcio and Salvi, Sundeep and Yorgancioğlu, Arzu and Zhang, Min and Brusselle, Guy},
  title = {2026 Global Initiative for Asthma (GINA) strategy report: executive summary and key changes},
  journal = {European Respiratory Journal},
  year = {2026},
  pages = {2602304},
  doi = {10.1183/13993003.02304-2026}
}
Kostenlos starten →